TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Core Insights - TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing T cell receptor (TCR)-engineered T cell (TCR-T) therapies for cancer treatment [3] Group 1: Company Overview - TScan's lead TCR-T therapy candidate is aimed at treating patients with hematologic malignancies to prevent relapse after allogeneic hematopoietic cell transplantation, specifically in the ALLOHA Phase 1 heme trial [3] - The company has developed multiple TCR-T therapy candidates targeting solid tumors and is working on in vivo engineering methods for these candidates [3] - TScan is also utilizing its target discovery platform to identify novel targets in various T cell-mediated autoimmune disorders [3] Group 2: Upcoming Events - TScan will participate in a hybrid presentation and analyst-led Q&A session at the TD Cowen 46 Annual Health Care Conference on March 4, 2026, at 11:50 a.m. Eastern Time [1] - A webcast of the presentation will be available on the company's website, with an archived replay accessible for 90 days post-event [2]